

Registered number: 08240913
Charity number: 1149758

ARK CANCER CHARITY
(A Company Limited by Guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

ARK CANCER CHARITY
(A Company Limited by Guarantee)

CONTENTS

| | Page |
|---|---------|
| Reference and Administrative Details of the Company, its Trustees and Advisers | 1 |
| Trustees' Report | 2 - 7 |
| Trustees' Responsibilities Statement | 8 |
| Independent Examiner's Report | 9 - 10 |
| Statement of Financial Activities | 11 |
| Balance Sheet | 12 - 13 |
| Statement of Cash Flows | 14 |
| Notes to the Financial Statements | 15 - 29 |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 DECEMBER 2024**

Trustees

M Rees
S Fell, Chair
R Finlayson
I Harrison

Company registered number

08240913

Charity registered number

1149758

Registered office

The Ark Conference Centre, Dinwoodie Drive, Basingstoke, Hampshire, RG24 9NN

Company secretary

B Devereux

Accountants

Shaw Gibbs (Audit) Limited, Wey Court West, Union Road, Farnham, Surrey, GU9 7PT

ARK CANCER CHARITY
(A Company Limited by Guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees (who are also directors of the Charity for the purposes of the Companies Act) present their annual report, which is also the directors' report, together with the financial statements of Ark Cancer Charity (the company) for the year ended 31 December 2024. The Trustees confirm that the Annual Report and Financial Statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (effective 1 January 2019).

Since the Company qualifies as small under section 383, the Strategic Report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 is not required.

Structure, management and governance

● **Structure**

Ark Cancer Charity is a Company Limited by Guarantee (No: 8240913) and a Charity Registered in England and Wales (No: 1149758). It is governed by its Memorandum and Articles of Association. The Trustees constitute Directors of the Charity for the purposes of company law.

Ark Cancer was registered as a company on 4th October 2012. It was registered as a charity on 14th November 2012.

Emphasis is placed on the skills of the Trustees to ensure Trustees' full contribution to the Charity's development.

● **Management**

The management of the Charity falls into three areas of responsibility:

1. The management of the Charity are dedicated to enhance the experience of cancer patients receiving treatment at Hampshire Hospital Foundation Trust. Through the grants policy, we are able to fund the Wellbeing Service which the NHS currently cannot provide.
2. Communication:
The Trustees will ensure that the aims of the Charity are projected with accuracy and clarity to the general public, across all fundraising activities and initiatives to ensure a true reflection of its objects.
3. Finance and administration:
Responsibility for the accounting, secretarial, legal and administrative requirements of the Charity are managed by the Trustees.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, management and governance (continued)

● **Governance**

1. Objectives and Activities

The Charity's objects as stated in its Articles of Association are:

The relief of sickness and the preservation of health and to assist in the treatment and care of persons affected by cancer through the enhancements of all aspects of cancer care including:

- i. providing or assisting in the provision of equipment, facilities and services ancillary or supplemental to those provided by the statutory authorities or other care providers.
- ii. to provide or assist in the provision of funding for enhanced or improved fitting out and decoration or any improvement to the aesthetic aspects of new or existing cancer care centres run by the statutory authorities or other care providers to enhance the wellbeing of persons affected by cancer.
- iii. providing or assisting in the provision of; or providing funding for statutory authorities or other care providers to provide, ancillary and complementary care services and therapies to enhance the wellbeing of persons affected by cancer.
- iv. provide support, assistance and information directly or indirectly to people affected by cancer and their carers, families and friends.
- v. promote and influence effective care, involvement and support for people affected by cancer, their carers, families and friends.

The furtherance of such objects and purposes to be carried out in North Hampshire or generally in the United Kingdom being objects and purposes which are exclusively charitable according the law of England and Wales.

2. Public Benefit

The Charity has looked at the public benefits of its objectives and has concluded that there is significant evidence highlighting that offering treatment in a pleasant, interesting, innovative environment benefits patients and greatly improves the outcome of their treatment. The grants will ensure the provision of:

- i. Services within an exceptional setting where the environment will help to elevate the psychological wellness of patients and their families. Evidence substantiates those administering treatments within an uplifting facility contributes positively to patients and enhances the effectiveness of their cancer treatment.
- ii. A range of support therapies, i.e. psychological support, survivorship courses, access to health, fitness, complementary therapies, etc. plus comprehensive information resources. These services will enable patients to manage their condition throughout diagnosis and treatment to assist people living with cancer and their families.

In summary the public benefit of Ark Cancer Charity is to ensure that enhanced facilities are available for anyone who needs support, whether they are receiving treatment or are family members engaged in supporting a sufferer during or after their treatment.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Structure, management and governance (continued)

Therefore the Trustees believe that they have complied with the duty to have due regard to guidance published by the Charity Commission.

Plans for future periods

To meet the increasing demand for our services, we plan to extend the Centre's facilities by adding additional rooms to accommodate more clinics. This expansion will allow us to reach more patients and provide them with the support they need.

● **Grant making policy**

Funding is made available to Hampshire Hospitals NHS Foundation Trust via grants. Grants are made to Hampshire Hospitals NHS Foundation Trust at the Trustees' discretion. The Trustees assess all bids from Hampshire Hospitals NHS Foundation Trust to ensure that the Charity would not be substituting other funding sources for standard NHS provision but would be contributing to enhancing what is expected over and above that which will be provided by Hampshire Hospitals NHS Foundation Trust.

Grant requests to provide integrated access to complementary therapies and support services are required to demonstrate that they meet at least one of the following objectives in order to be considered for funding:

- i. Enhancing the quality of care received by patients and families over and above the NHS standard provision.
- ii. Improving patient confidence in care provided.
- iii. Pump priming and supporting innovation.
- iv. Supporting the development and growth of the Wellbeing Centre to enable access to more patients.
- v. Attraction, retention and development of staff of the highest calibre.

Grants are not made to any other organisation or individual.

Once a grant has been approved the commitment is recognised and the grant is paid in agreed instalments over the duration of the project.

Financial review

● **Investment policy**

The Charity Trustees have agreed that cash deposits should be held in fixed term interest bearing accounts which will ensure that funds can be accessed promptly, strategically and operationally as demands arise. In the previous year, the Trustees agreed to designate £1,500,000 towards the future funding of the Wellbeing Centre, of which at the year end the closing balance of the fund is at £1,062,000.

The Charity Trustees have also agreed to designate £1,000,000 towards the future refurbishment of the Rainbow Unit which has been expended at the year end.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

● **Reserves policy**

At the year end the Charity held unrestricted reserves of £1,324,029 (2023 - £2,655,918) of which £1,062,000 (2023 - £2,381,389) was designated by the Trustees.

The Reserves Policy will be subject to an annual review, conducted at the end of each financial year. This review will take into account the projected budget for the upcoming year, allowing the trustees to assess the adequacy of the existing reserves.

Achievements and performance

● **Main achievements**

Basingstoke Chemotherapy Unit

During the 2020 Covid pandemic, chemotherapy treatments at Basingstoke Hospital were moved to a standalone unit to ensure the safety of patients and staff by isolating them away from the main hospital building. Recognising the success of this arrangement, the Ark Cancer Charity funded an extensive renovation of this unit to create a more cohesive and efficient working and treatment environment.

Collaborating with a team of architects, the Charity conducted a feasibility study to plan the renovation following which the hospital appointed an Estate Project Manager and Clinical Project Manager to oversee the project during the refurbishment process. The works took place from July to October 2024. Both staff and patients actively participated in selecting appropriate colour schemes and styles of artwork for the internal design, ensuring a thoughtful and inclusive approach to the unit's aesthetics.

Greenham Trust generously agreed to release the £500,000 of match funding previously raised through their fundraising platform by supportive donors of Ark Cancer Charity. They also approved a further £50,000 towards the costs of the relocation of the chemotherapy unit to a temporary home for the duration of the refurbishment works, having recognised our contribution to the local community and in honouring us in November 2023 with the Health & Wellbeing Charity of the Year Award during the inaugural Greenham Trust Charity Awards Ceremony in Newbury. The charity is extremely grateful for their ongoing support.

This award not only acknowledges the outstanding achievements of our Charity but also highlights the positive impact we have made on the community's health and wellbeing.

Wellbeing Services

The Ark Cancer Charity's Wellbeing Centre continues to positively impact the community by providing much-needed support services to cancer outpatients.

It has become a vital community resource, offering complementary therapies and counselling services at Hampshire Hospitals NHS Foundation Trust. The Centre serves a wide range of cancer outpatients, demonstrating its ability to cater to diverse needs, including breast, gynaecological, haematological, prostate, colorectal, upper gastrointestinal, and lung cancer patients. This inclusivity ensures that a broad range of individuals can access tailored support.

By offering complementary therapies alongside conventional medical care, the Centre promotes healing that encompasses both physical and emotional wellbeing. Patients benefit from a comprehensive approach that addresses treatment side effects and emotional challenges.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance (continued)

The Centre's team of experienced therapists and counsellors bring a wealth of knowledge to patient care. Their adherence to NHS guidelines and collaboration with clinical colleagues ensures that patients receive evidence-based, integrated care. By collecting and utilising patient feedback, the centre demonstrates its commitment to putting patients at the forefront of its services. This approach not only improves care quality but also offers insights to HHFT clinicians regarding treatment outcomes and patient experiences. Various case studies have highlighted the Centre's therapies leading to positive outcomes such as alleviating treatment side effects, aiding post-operative recovery, and supporting patients through challenging treatments such as radiotherapy.

The Charity has provided additional space within the newly refurbished chemotherapy unit for these services and has increased the grants available in 2024 in line with the increasing demand.

Hilotherm

Chemotherapy, a crucial part of cancer treatment, often leads to various side effects, with chemotherapy-induced peripheral neuropathy (CIPN) being a well-known concern. This condition predominantly affects the hands and feet of cancer patients, resulting in severe pain, discomfort, tingling, numbness, and balance issues.

The Hilotherm machine is a tailored solution designed to prevent or minimise the adverse effects of CIPN and HFS and following a successful trial at Basingstoke Hospital, we were able to fund the purchase of a further machine at Basingstoke, and two machines for the chemotherapy department at Winchester. These specific purchases were made possible through a further generous donation by The Edwina Mountbatten and Leonora Children's Foundation who have supported this project from the outset.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Achievements and performance (continued)

• **Fundraising activity over the past year**

Throughout the year, our charity has continued its fundraising efforts via online platforms and has received consistent support from various community groups. The 50:50 initiative has maintained its popularity, contributing to our fundraising success.

In November 2024, we recruited a Fundraising Manager to increase our activities, building on all of the good work which has been carried out in the past so that we can continue to fund the demand for our patient-centred wellbeing services.

We extend our heartfelt gratitude to everyone involved—our dedicated team members, supporters, and the community at large. They inspire us to continue our fundraising with renewed vigour, knowing that our collective efforts are making a meaningful difference in the lives of those we serve, and we look forward to continuing our journey towards creating a positive impact in the community.

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

Approved by order of the members of the board of Trustees and signed on their behalf by:

S Fell
(Trustee)

Date:

S Fell

16/12/25

ARK CANCER CHARITY
(A Company Limited by Guarantee)

STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees (who are also the directors of the Company for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

S Fell
(Trustee)
Date:

S/fell
16/9/25

ARK CANCER CHARITY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024

Independent Examiner's Report to the Trustees of Ark Cancer Charity ('the Company')

I report to the charity Trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and Basis of Report

As the Trustees of the Company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Company's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of (enter body here), which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

INDEPENDENT EXAMINER'S REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

This report is made solely to the Company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Company's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Company and the Company's Trustees as a body, for my work or for this report.

Signed: *M. Dickinson*

Dated: *19/09/2025*

Mark Dickinson (FCA)

Shaw Gibbs (Audit) Limited
Wey Court West
Union Road
Farnham
Surrey
GU9 7PT

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2024**

| | Note | Unrestricted funds 2024 £ | Total funds 2024 £ | Total funds 2023 £ |
|------------------------------------|------|------------------------------------|-----------------------------|-----------------------------|
| Income from: | | | | |
| Donations and legacies | 3 | 688,736 | 688,736 | 37,415 |
| Other trading activities | 4 | 34,817 | 34,817 | 30,075 |
| Investments | 5 | 82,266 | 82,266 | 69,541 |
| Total income | | 805,819 | 805,819 | 137,031 |
| Expenditure on: | | | | |
| Raising funds | 6 | 3,609 | 3,609 | 2,614 |
| Charitable activities | | 2,134,100 | 2,134,100 | 139,087 |
| Total expenditure | | 2,137,709 | 2,137,709 | 141,701 |
| Net movement in funds | | (1,331,890) | (1,331,890) | (4,670) |
| Reconciliation of funds: | | | | |
| Total funds brought forward | | 2,655,918 | 2,655,918 | 2,660,588 |
| Net movement in funds | | (1,331,890) | (1,331,890) | (4,670) |
| Total funds carried forward | | 1,324,028 | 1,324,028 | 2,655,918 |

The notes on pages 15 to 29 form part of these financial statements.

ARK CANCER CHARITY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 08240913

BALANCE SHEET
AS AT 31 DECEMBER 2024

| | Note | 2024 £ | 2023 £ |
|--|------|-------------------------|-------------------------|
| Fixed assets | | | |
| Tangible assets | 11 | 8,341 | 7,010 |
| Current assets | | | |
| Debtors | 12 | 581,676 | 9,838 |
| Investments | 13 | 1,000,000 | 2,058,596 |
| Cash at bank and in hand | | 1,539,914 | 677,932 |
| | | <u>3,121,590</u> | <u>2,746,366</u> |
| Creditors: amounts falling due within one year | 14 | (1,805,902) | (97,458) |
| Net current assets | | <u>1,315,688</u> | <u>2,648,908</u> |
| Total net assets | | <u><u>1,324,029</u></u> | <u><u>2,655,918</u></u> |
| Charity funds | | | |
| Unrestricted funds: | | | |
| Wellbeing complimentary therapies | 15 | 366,000 | 366,000 |
| Wellbeing mental health services | 15 | 696,000 | 623,634 |
| Rainbow unit project | 15 | - | 1,391,755 |
| General funds | 15 | 262,029 | 274,529 |
| Total unrestricted funds | 15 | <u>1,324,029</u> | <u>2,655,918</u> |
| Total funds | | <u><u>1,324,029</u></u> | <u><u>2,655,918</u></u> |

ARK CANCER CHARITY
(A Company Limited by Guarantee)
REGISTERED NUMBER: 08240913

BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2024

The Company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

S Fell
Trustee

Date:

SIFell

16/9/25

The notes on pages 15 to 29 form part of these financial statements.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024

| | Note | 2024 £ | 2023 £ |
|---|------|-----------|-----------|
| Cash flows from operating activities | | | |
| Net cash used in operating activities | 18 | (275,617) | (160,200) |
| Cash flows from investing activities | | | |
| Purchase of tangible fixed assets | | (3,263) | (6,335) |
| Net cash used in investing activities | | (3,263) | (6,335) |
| Cash flows from financing activities | | | |
| Dividends, interest and rents from investments | | 82,266 | 69,541 |
| Net cash provided by financing activities | | 82,266 | 69,541 |
| Change in cash and cash equivalents in the year | | (196,614) | (96,994) |
| Cash and cash equivalents at the beginning of the year | | 2,736,528 | 2,833,522 |
| Cash and cash equivalents at the end of the year | 19 | 2,539,914 | 2,736,528 |

The notes on pages 15 to 29 form part of these financial statements

ARK CANCER CHARITY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. General information

Ark Cancer Charity is a private company, limited by guarantee without share capital and incorporated in England. Its registered office address is The Ark Conference Centre, Dinwoodie Drive, Basingstoke, Hampshire, RG24 9NN.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Ark Cancer Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Income

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

The recognition of income from legacies is dependent on establishing entitlement, the probability of receipt and the ability to estimate with sufficient accuracy the amount receivable. Evidence of entitlement to a legacy exists when the Company has sufficient evidence that a gift has been left to them (through knowledge of the existence of a valid will and the death of the benefactor) and the executor is satisfied that the property in question will not be required to satisfy claims in the estate. Receipt of a legacy must be recognised when it is probable that it will be received and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the Company, can be reliably measured.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Donated services or facilities are recognised when the Company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the Company which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Company's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.4 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Company; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.5 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

At each reporting date the Company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined to be the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

| | |
|--------------------|---------------------------|
| Computer equipment | - 20% straight line basis |
|--------------------|---------------------------|

ARK CANCER CHARITY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

2. Accounting policies (continued)

2.6 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.7 Current asset investments

Current asset investments include short-term deposits with a maturity of more than three months from the date of opening of the deposit or similar account.

2.8 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

2.9 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

2.10 Financial instruments

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.11 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

3. Income from donations and legacies

| | Unrestricted funds 2024 £ | Total funds 2024 £ |
|-----------|--|---------------------------------------|
| Donations | 43,736 | 43,736 |
| Legacies | 95,000 | 95,000 |
| Grants | 550,000 | 550,000 |
| | <u>688,736</u> | <u>688,736</u> |

Included in donations is £8,097 (2023 - £17,540) estimated as the cost of salaries donated.
Grants receivable are from the Greenham Trust for the refurbishment costs of the Oncology Centre.

| | <i>Unrestricted funds 2023 £</i> | <i>Total funds 2023 £</i> |
|-----------|--|---------------------------------------|
| Donations | 28,124 | 28,124 |
| Legacies | 9,291 | 9,291 |
| Grants | - | - |
| | <u>37,415</u> | <u>37,415</u> |

4. Income from charitable activities

Income from fundraising events

| | Unrestricted funds 2024 £ | Total funds 2024 £ |
|--------------------|--|---------------------------------------|
| Income from events | 34,817 | 34,817 |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

4. Income from charitable activities (continued)

Income from fundraising events (continued)

| | <i>Unrestricted funds 2023 £</i> | <i>Total funds 2023 £</i> |
|--------------------|--|---------------------------------------|
| Income from events | 30,075 | 30,075 |

5. Investment income

| | <i>Unrestricted funds 2024 £</i> | <i>Total funds 2024 £</i> |
|--------------------------|--|---------------------------------------|
| Bank interest receivable | 82,266 | 82,266 |

| | <i>Unrestricted funds 2023 £</i> | <i>Total funds 2023 £</i> |
|--------------------------|--|---------------------------------------|
| Bank interest receivable | 69,541 | 69,541 |

6. Expenditure on raising funds

Costs of raising voluntary income

| | <i>Unrestricted funds 2024 £</i> | <i>Total funds 2024 £</i> |
|------------------------------|--|---------------------------------------|
| Event costs | - | - |
| Online donation fees | 676 | 676 |
| Cost of marketing and prizes | 2,933 | 2,933 |
| | 3,609 | 3,609 |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

6. Expenditure on raising funds (continued)

Costs of raising voluntary income (continued)

| | <i>Unrestricted funds 2023 £</i> | <i>Total funds 2023 £</i> |
|-------------------------------|--|---------------------------------------|
| Online donation fees | 216 | 216 |
| Costs of marketing and prizes | 2,398 | 2,398 |
| | <u>2,614</u> | <u>2,614</u> |

7. Analysis of expenditure on charitable activities

| | <i>Activities undertaken directly 2024 £</i> | <i>Grant funding of activities 2024 £</i> | <i>Support costs 2024 £</i> | <i>Total funds 2024 £</i> |
|--------------|--|---|---|---------------------------------------|
| Direct costs | <u>1,844,398</u> | <u>256,276</u> | <u>33,426</u> | <u>2,134,100</u> |

| | <i>Activities undertaken directly 2023 £</i> | <i>Grant funding of activities 2023 £</i> | <i>Support costs 2023 £</i> | <i>Total funds 2023 £</i> |
|--------------|--|---|---|---------------------------------------|
| Direct costs | <u>108,245</u> | <u>10,366</u> | <u>20,476</u> | <u>139,087</u> |

Included in support costs is £8,097 (2023 - £17,540) estimated as the cost of salaries donated.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

7. Analysis of expenditure on charitable activities (continued)

Analysis of direct costs

| | Direct costs - Activities 2024 £ | Total funds 2024 £ |
|----------------------------------|---|---------------------------------------|
| Rainbow unit refurbishment costs | 1,844,398 | 1,844,398 |

| | <i>Direct costs - Activities 2023 £</i> | <i>Total funds 2023 £</i> |
|----------------------------------|---|---------------------------------------|
| Rainbow unit refurbishment costs | 108,245 | 108,245 |

Analysis of support costs

| | Total funds 2024 £ | Total funds 2023 £ |
|------------------------|---------------------------------------|---------------------------------------|
| Fees/subscriptions | 441 | 661 |
| Miscellaneous costs | 432 | (34) |
| Website costs | 147 | 487 |
| Recharged salary costs | 8,619 | 6,290 |
| Stationery | 1,040 | 1,096 |
| Telephone | 301 | - |
| Governance costs | 22,446 | 11,976 |
| | 33,426 | 20,476 |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

8. Analysis of grants

| | Grants to Institutions 2024 £ | Total funds 2024 £ |
|---|--|---------------------------------------|
| Grants to Hampshire Hospitals NHS Foundation Trust in support of the Wellbeing Centre | <u>256,276</u> | <u>256,276</u> |
| | | |
| | Grants to Institutions 2023 £ | Total funds 2023 £ |
| Grants to Hampshire Hospitals NHS Foundation Trust in support of the Wellbeing Centre | <u>10,366</u> | <u>10,366</u> |

9. Independent examiner's remuneration

The independent examiner's remuneration amounts to an independent examiner fee of £3,450 (2023 - £3,270).

10. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 31 December 2024, expenses totalling £147 were paid directly to 1 Trustee (2023 - £NIL) The expenses incurred were reimbursement of purchases on behalf of the charity.

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

11. Tangible fixed assets

| | Computer equipment £ |
|--------------------------|----------------------------|
| Cost or valuation | |
| At 1 January 2024 | 9,669 |
| Additions | 3,263 |
| At 31 December 2024 | <u>12,932</u> |
| Depreciation | |
| At 1 January 2024 | 2,659 |
| Charge for the year | 1,932 |
| At 31 December 2024 | <u>4,591</u> |
| Net book value | |
| At 31 December 2024 | <u><u>8,341</u></u> |
| At 31 December 2023 | <u><u>7,010</u></u> |

12. Debtors

| | 2024 £ | 2023 £ |
|--------------------------------|-----------------------|---------------------|
| Prepayments and accrued income | <u><u>581,676</u></u> | <u><u>9,838</u></u> |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

13. Current asset investments

| | 2024 | 2023 |
|-----------------------|------------------|------------------|
| | £ | £ |
| Term deposit accounts | 1,000,000 | 2,058,596 |

14. Creditors: Amounts falling due within one year

| | 2024 | 2023 |
|------------------------------|------------------|---------------|
| | £ | £ |
| Accruals and deferred income | 1,805,902 | 97,458 |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

15. Statement of funds

Statement of funds - current year

| | Balance at 1 January 2024 £ | Income £ | Expenditure £ | Transfers in/out £ | Balance at 31 December 2024 £ |
|-----------------------------------|--------------------------------------|-----------------------|---------------------------|--------------------------|---|
| Unrestricted funds | | | | | |
| Designated funds | | | | | |
| Wellbeing complimentary therapies | 366,000 | - | - | - | 366,000 |
| Wellbeing mental health services | 623,634 | - | (256,276) | 328,642 | 696,000 |
| Rainbow unit project | 1,391,755 | 582,000 | (1,844,398) | (129,357) | - |
| | <u>2,381,389</u> | <u>582,000</u> | <u>(2,100,674)</u> | <u>199,285</u> | <u>1,062,000</u> |
| General funds | | | | | |
| General funds | <u>274,529</u> | <u>223,820</u> | <u>(37,035)</u> | <u>(199,285)</u> | <u>262,029</u> |
| Total Unrestricted funds | <u><u>2,655,918</u></u> | <u><u>805,820</u></u> | <u><u>(2,137,709)</u></u> | <u><u>-</u></u> | <u><u>1,324,029</u></u> |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

15. Statement of funds (continued)

Statement of funds - prior year

| | <i>Balance at 1 January 2023 £</i> | <i>Income £</i> | <i>Expenditure £</i> | <i>Balance at 31 December 2023 £</i> |
|-----------------------------------|--|-----------------------|--------------------------|--|
| Unrestricted funds | | | | |
| Designated funds | | | | |
| Wellbeing complimentary therapies | 366,000 | - | - | 366,000 |
| Wellbeing mental health services | 634,000 | - | (10,366) | 623,634 |
| Rainbow unit project | 1,500,000 | - | (108,245) | 1,391,755 |
| | <u>2,500,000</u> | <u>-</u> | <u>(118,611)</u> | <u>2,381,389</u> |
| General funds | | | | |
| General funds | <u>160,587</u> | <u>137,032</u> | <u>(23,090)</u> | <u>274,529</u> |
| Total Unrestricted funds | <u><u>2,660,587</u></u> | <u><u>137,032</u></u> | <u><u>(141,701)</u></u> | <u><u>2,655,918</u></u> |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

16. Summary of funds

Summary of funds - current year

| | Balance at 1 January 2024 £ | Income £ | Expenditure £ | Transfers in/out £ | Balance at 31 December 2024 £ |
|------------------|--------------------------------------|----------------|--------------------|--------------------------|---|
| Designated funds | 2,381,389 | 582,000 | (2,100,674) | 199,285 | 1,062,000 |
| General funds | 274,529 | 223,820 | (37,035) | (199,285) | 262,029 |
| | <u>2,655,918</u> | <u>805,820</u> | <u>(2,137,709)</u> | <u>-</u> | <u>1,324,029</u> |

Summary of funds - prior year

| | Balance at 1 January 2023 £ | Income £ | Expenditure £ | Balance at 31 December 2023 £ |
|------------------|--------------------------------------|----------------|------------------|---|
| Designated funds | 2,500,000 | - | (118,611) | 2,381,389 |
| General funds | 160,587 | 137,032 | (23,090) | 274,529 |
| | <u>2,660,587</u> | <u>137,032</u> | <u>(141,701)</u> | <u>2,655,918</u> |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

17. Analysis of net assets between funds

Analysis of net assets between funds - current period

| | Unrestricted funds 2024 £ | Total funds 2024 £ |
|-------------------------------|--|---------------------------------------|
| Tangible fixed assets | 8,341 | 8,341 |
| Current assets | 3,121,590 | 3,121,590 |
| Creditors due within one year | (1,805,902) | (1,805,902) |
| Total | 1,324,029 | 1,324,029 |

18. Reconciliation of net movement in funds to net cash flow from operating activities

| | 2024 £ | 2023 £ |
|---|-------------------|-------------------|
| Net expenditure for the period (as per Statement of Financial Activities) | (1,331,890) | (4,670) |
| Adjustments for: | | |
| Depreciation charges | 1,932 | 1,125 |
| Dividends, interests and rents from investments | (82,266) | (69,541) |
| Decrease/(increase) in debtors | (571,838) | (785) |
| Increase/(decrease) in creditors | 1,708,445 | (86,329) |
| Net cash used in operating activities | (275,617) | (160,200) |

19. Analysis of cash and cash equivalents

| | 2024 £ | 2023 £ |
|--|-------------------|-------------------|
| Cash in hand | 123,050 | 159,919 |
| Notice deposits (less than 3 months) | 1,416,864 | 518,013 |
| Term deposits (more than 1 year) | 1,000,000 | 2,058,596 |
| Total cash and cash equivalents | 2,539,914 | 2,736,528 |

ARK CANCER CHARITY
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

20. Analysis of changes in net debt

| | At 1 January 2024 £ | Cash flows £ | At 31 December 2024 £ |
|--------------------------|------------------------------|------------------|--------------------------------|
| Cash at bank and in hand | 677,932 | 861,982 | 1,539,914 |
| Term deposit accounts | 2,058,596 | (1,058,596) | 1,000,000 |
| | <u>2,736,528</u> | <u>(196,614)</u> | <u>2,539,914</u> |

21. Operating lease commitments

At 31 December 2024 the Company had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

| | 2024 £ | 2023 £ |
|--|--------------|--------------|
| Equipment | | |
| Not later than 1 year | 755 | 1,250 |
| Later than 1 year and not later than 5 years | 378 | 1,133 |
| | <u>1,133</u> | <u>2,383</u> |

22. Members' liability

Each member of the charitable Company undertakes to contribute to the assets of the Company in the event of it being wound up while he/she is a member, or within one year after he/she ceases to be a member, such amount as may be required, not exceeding £1 for the debts and liabilities contracted before he/she ceases to be a member.

23. Related party transactions

During the year a Trustee of the charity had an honorary contract with Hampshire Hospitals NHS Foundation Trust, in the form of salary recharged costs, amounted to £7,450.

24. Controlling party

During the year, the charity was under the control of the Trustees.